tert-butyl N-[[1-[(5-bromo-2-chloro-4H-pyrimidin-3-yl)amino]cyclohexyl]methyl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: tert-butyl N-[[1-[(5-bromo-2-chloro-4H-pyrimidin-3-yl)amino]cyclohexyl]methyl]carbamate
• 化学式: C₁₆H₂₆BrClN₄O₂
• 分子量: 421.8
• InChiKey: PJJOFWSGTFUJCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS<br/>[FR] COMPOSÉS ANTI-PROLIFÉRATIFS À BASE DE PYRIMIDINE.
  申请人：G1 THERAPEUTICS INC

  公开号：WO2018005533A1

  公开（公告）日：2018-01-04

  This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

  这项发明涉及以嘧啶为基础的化合物，用于治疗涉及异常细胞增殖的疾病，包括但不限于肿瘤和癌症。
• CDK Inhibitors
  申请人：G1 Therapeutics, Inc.

  公开号：US20140142299A1

  公开（公告）日：2014-05-22

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  式子I、II或III的化合物及其药学上可接受的盐，可用作CDK抑制剂。
• [EN] TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION<br/>[FR] LACTAMES TRICYCLIQUES À UTILISER DANS DES TRAITEMENTS DE LA PROLIFÉRATION DE CELLULES ANORMALES RB-POSITIVES, ÉPARGNANT LES CELLULES SOUCHES ET LES CELLULES PROGÉNITRICES HÉMATOPOÏÉTIQUES (HSPC)
  申请人：G1 THERAPEUTICS INC

  公开号：WO2015161283A1

  公开（公告）日：2015-10-22

  This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.